Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Sign or Symptom > Hemoptysis

Hemoptysis

Hemoptysis refers to the expectoration of blood or blood-tinged sputum originating from the lower respiratory tract.
It can be a symptom of various underlying conditions, such as lung infections, lung cancer, pulmonary embolism, or cardiovascular diseases.
PubCompare.ai's AI-driven platform can help researchers optimize their investigations into hemoptysis by easily locating and comparing protocols from literature, preprints, and patents.
This advanced tool takes the guesswork out of the research process, ensuring reliable and reproducible results that advance the understanding and management of this important clinical condition.

Most cited protocols related to «Hemoptysis»

1
National Lung Screening Trial Protocol
Cited 109 times
We enrolled participants from August 2002 through April 2004; screening took place from August 2002 through September 2007. Participants were followed for events that occurred through December 31, 2009 (Fig. 1 in the Supplementary Appendix, available at NEJM.org).
Eligible participants were between 55 and 74 years of age at the time of randomization, had a history of cigarette smoking of at least 30 pack-years, and, if former smokers, had quit within the previous 15 years. Persons who had previously received a diagnosis of lung cancer, had undergone chest CT within 18 months before enrollment, had hemoptysis, or had an unexplained weight loss of more than 6.8 kg (15 lb) in the preceding year were excluded. A total of 53,454 persons were enrolled; 26,722 were randomly assigned to screening with low-dose CT and 26,732 to screening with chest radiography. Previously published articles describing the NLST10 (link),12 (link) reported an enrollment of 53,456 participants (26,723 in the low-dose CT group and 26,733 in the radiography group). The number of enrolled persons is now reduced by 2 owing to the discovery of the duplicate randomization of 2 participants.
Participants were enrolled at 1 of the 10 LSS or 23 ACRIN centers. Before randomization, each participant provided written informed consent. After the participants underwent randomization, they completed a questionnaire that covered many topics, including demographic characteristics and smoking behavior. The ACRIN centers collected additional data for planned analyses of cost-effectiveness, quality of life, and smoking cessation. Participants at 15 ACRIN centers were also asked to provide serial blood, sputum, and urine specimens. Lung-cancer and other tissue specimens were obtained at both the ACRIN and LSS centers and were used to construct tissue microarrays. All biospecimens are available to researchers through a peer-review process.
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. (2011). The New England journal of medicine, 365(5), 395-409.
Publication 2011
BLOOD Chest Diagnosis Hemoptysis Lung Cancer Microarray Analysis Peer Review Radiography, Thoracic Sputum Tissues Urine X-Rays, Diagnostic
2
Tuberculosis and HIV Screening Study in Lima, Peru
Cited 13 times
The study was conducted in Lima, Peru, from April 2003 through July 2004
in three target groups, with consecutive recruitment. The first group consisted
of otherwise unselected patients who presented with suspected tuberculosis to
the National TB Programme at 10 government clinics in north Lima. The second
consisted of patients who presented with suspected tuberculosis to the National
TB Programme at five government clinics in east Lima and who were at high risk
for tuberculosis or multidrug-resistant tuberculosis. Inclusion in this group
required the presence of one or more constitutional symptoms (fever, weight
loss, night sweats, hemoptysis) or one risk factor for tuberculosis or
multidrug-resistant tuberculosis (prior treatment for tuberculosis, known
contact with a patient with tuberculosis, infection with human immunodeficiency
virus [HIV], employment as a health care or prison
worker, hospitalization during the previous year, or any previous
incarceration). The third group consisted of otherwise unselected hospitalized
patients with HIV infection at two Lima hospitals, regardless of the diagnosis
on admission. Exclusion criteria for all groups were an age under 18 years or an
inability or unwillingness to give written informed consent. Study protocol and
consent forms were approved by the institutional review boards of Universidad
Peruana Cayetano Heredia, Asociación Benéfica PRISMA,
Dirección de Salud–III Lima Norte and
Dirección de Salud–IV Lima Este (regional Ministry of
Health), Hospital Nacional Hipolito Unanue, Hospital Nacional General Arzobispo
Loayza, Johns Hopkins Bloomberg School of Public Health, and Imperial College
London.
Moore D.A., Evans C.A., Gilman R.H., Caviedes L., Coronel J., Vivar A., Sanchez E., Piñedo Y., Saravia J.C., Salazar C., Oberhelman R., Hollm-Delgado M.G., LaChira D., Escombe A.R, & Friedland J.S. (2006). Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB. The New England journal of medicine, 355(15), 1539-1550.
Publication 2006
Ethics Committees, Research Fever Hemoptysis Homo sapiens Hospitalization Infection Infections, Hospital Patients prisma Sweat Tuberculosis Tuberculosis, Multidrug-Resistant
3
Diagnosing Community-Acquired Pneumonia
Cited 7 times
Adults (aged ≥18 years) presenting to the emergency department with a suspicion of CAP and fulfilling at least two of the following criteria: new or worsening cough, new or worsening expectoration of sputum, new or worsening dyspnoea, hemoptysis, pleuritic chest pain, radiological evidence of pneumonia, abnormalities on chest auscultation and/or percussion, and fever (≥38.0°C).
Written informed consent is needed from the patient or from their legal guardian/close relative at the time of recruitment.
Serigstad S., Ritz C., Faurholt-Jepsen D., Markussen D., Ebbesen M.H., Kommedal Ø., Bjørneklett R.O., Heggelund L., Clark T.W., van Werkhoven C.H., Knoop S.T., Ulvestad E, & Grewal H.M. (2022). Impact of rapid molecular testing on diagnosis, treatment and management of community-acquired pneumonia in Norway: a pragmatic randomised controlled trial (CAPNOR). Trials, 23, 622.
Publication 2022
Adult Auscultation Chest Chest Pain Congenital Abnormality Cough Dyspnea Fever Hemoptysis Legal Guardians Patients Percussion Pleurisy Pneumonia Sputum X-Rays, Diagnostic
4
Rapid Syndromic PCR in Community-Acquired Pneumonia
Cited 6 times
This was a prospectively recruited cohort study conducted at Haukeland University Hospital, a tertiary care referral centre in Bergen, Norway between December 2nd 2019, and February 17th 2020. In addition to conventional microbiological diagnostics, samples from the lower respiratory tract were systematically analysed with a commercial rapid syndromic PCR panel, the FAP plus. The study was conducted as a feasibility study to inform the design of a larger randomised controlled trial evaluating the clinical impact of the FAP plus assay on antibiotic use and outcome (NCT04660084). Patients were eligible for inclusion if they were ≥ 18 years, presenting to the emergency department (ED) with a suspicion of CAP (evaluated by investigating physicians and/or study nurses) and fulfilling at least two of the following criteria: new or worsening cough; new or worsening expectoration of sputum; new or worsening dyspnoea; haemoptysis; pleuritic chest pain; radiological evidence of pneumonia; abnormalities on chest auscultation and/or percussion; fever (≥ 38.0 °C). Exclusion criteria were cystic fibrosis, severe bronchiectasis (defined as patients in need of regular follow-up and treatment by a pulmonologist due to bronchiectasis), hospitalisation within the last 14 days prior to admission, a palliative approach (defined as life expectancy below two weeks documented by a treating physician; either by preexisting estimates in the electronic journal, or estimations made at admission), or if the patient was not willing or able to provide a lower respiratory tract sample (by either sputum induction or endotracheal aspiration).
Serigstad S., Markussen D., Grewal H.M., Ebbesen M., Kommedal Ø., Heggelund L., van Werkhoven C.H., Faurholt-Jepsen D., Clark T.W., Ritz C., Ulvestad E., Bjørneklett R, & Knoop S.T. (2022). Rapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yield. Scientific Reports, 12, 326.
Publication 2022
Antibiotics Auscultation Biological Assay Bronchiectasis Chest Chest Pain Congenital Abnormality Cough Cystic Fibrosis Diagnosis Dyspnea Fever Hemoptysis Nurses Patients Percussion Physicians Pleurisy Pneumonia Pulmonologists Respiratory System Sputum Syndrome X-Rays, Diagnostic
5
Safety and Immunogenicity of COVID-19 Vaccine
Cited 6 times
The primary outcome of this trial was safety, which we assessed by the frequency and severity of vaccine-related local and systemic adverse events. Details of expected local skin adverse events (pain, erythema, and swelling), respiratory adverse events (cough, sore throat, wheeze, dyspnoea, sputum production, haemoptysis, chest pain, and appearance of bronchial mucosa), and systemic adverse events (fever, feverishness, fatigue, malaise, headache, myalgia, arthralgia, and nausea) were collected from participants by the use of a diary card, which the participants self-completed for 14 days after vaccination. We measured routine laboratory biochemical and haematological variables at 7 days and 84 days after vaccination. We issued participants with, and trained them in the use of, a handheld spirometer (Micro Spirometer, CareFusion [San Diego, CA, USA]) for home measurement of forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), initially twice daily and then daily for 14 days after vaccination. The secondary outcome was immunogenicity to both insert (Ag85A) and vector (MVA) assessed with laboratory markers of cell-mediated immunity in blood and bronchoalveolar lavage samples by use of ex-vivo interferon-γ ELISpot, intracellular cytokine staining, and serum ELISAs for humoral responses.
Satti I., Meyer J., Harris S.A., Thomas Z.R., Griffiths K., Antrobus R.D., Rowland R., Ramon R.L., Smith M., Sheehan S., Bettinson H, & McShane H. (2014). Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. The Lancet. Infectious Diseases, 14(10), 939-946.
Publication 2014
Antigens Arthralgia BLOOD Bronchi Bronchoalveolar Lavage Cellular Immunity Chest Pain Cloning Vectors Cough Cytokine Dyspnea Enzyme-Linked Immunosorbent Assay Enzyme-Linked Immunospot Assay Erythema Fatigue Fever Forced Vital Capacity Headache Hemoptysis Interferon Type II Mucous Membrane Myalgia Nausea Pain Protoplasm Respiratory Rate Safety Serum Skin Sore Throat Spirometry Sputum Vaccination Vaccines Volumes, Forced Expiratory Wheezing

Most recents protocols related to «Hemoptysis»

1
Breath-based Tuberculosis Diagnosis Model
We conducted a cross-sectional study from 1 March 2020 to 31 March 2021 at The Third People's Hospital of Shenzhen. The study was approved by the Ethics Committee of The Third People's Hospital of Shenzhen (number: 2020-012). Written informed consent was obtained from all participants.
The total participants consisted of a case group and a control group. For the case group, confirmed PTB patients were prospectively and consecutively recruited based on the following criteria: (1) aged 18–70 years old; (2) diagnosed by Xpert and/or culture, with suggestive clinical and radiological findings; (3) anti-TB treatment not initiated or started less than 2 weeks. The control group consists of two parts: healthy controls with no pulmonary diseases (HC) and patients with pulmonary diseases (unhealthy controls, UHC) which could be noninfectious diseases or infectious diseases other than PTB. HCs were simultaneously recruited and underwent a physical examination with the following criteria: (1) aged 18–70 years old; (2) no respiratory symptoms (e.g., cough, sputum, hemoptysis, shortness of breath, dyspnea, or chest pain); (3) no pulmonary lesions by chest imaging (chest X-ray or computed tomography). For UHC, they should: (1) aged 18–70 years old; (2) have pathogenic confirmed infectious diseases or treatment response suggestive of pulmonary infectious diseases, or have chronic noninfectious diseases, without evidence of infection. Both the case group and the control group would be excluded if the airbag leaked or were unable to take enough breath volume. The participant enrollment flow is illustrated in Fig. 1a. A total of 518 PTB patients and 887 controls with 77 UHC and 810 HC were enrolled in this study.

The flow of participants enrollment and PTB detection model construction and test

The physicians were responsible for making a clinical diagnosis and for the collection of the breath samples. The other researchers performed the VOCs detection and ML modeling and were blinded to clinical data and other test results. Additionally, the physicians were also blinded to the breath test results. The demographic and clinical characteristics of all participants were collected and summarized in Table 1, including age, sex, and antituberculosis therapy.

Demographic characteristics of participants

Discovery data setTest data set
PTB (N = 361)Control (N = 614)p-valuePTB (N = 157)Control (N = 273)p-value
Age
 Median (min.–max.)36 (18–70)28 (18–69) < 0.00132 (18–70)28 (18–70) < 0.001
  < 30 (%)115 (31.9)345 (56.2)0.00864 (40.8)169 (61.9)0.258
  ≥ 30 (%)246 (68.1)269 (43.8) < 0.00193 (59.2)104 (38.1)0.009
Sex
 Male (%)223 (61.8)325 (52.9)0.009101 (64.3)142 (52.0)0.004
 Female (%)138 (38.2)289 (47.1)–56 (35.7)131 (48.0)–

Bold p-value shows that there are significant differences between PTB and controls

Fu L., Wang L., Wang H., Yang M., Yang Q., Lin Y., Guan S., Deng Y., Liu L., Li Q., He M., Zhang P., Chen H, & Deng G. (2023). A cross-sectional study: a breathomics based pulmonary tuberculosis detection method. BMC Infectious Diseases, 23, 148.
Publication 2023
Breath Tests Chest Chest Pain Communicable Diseases Cough Diagnosis Disease, Chronic Dyspnea Ethics Committees, Clinical Hemoptysis Infection Lung Lung Diseases Males Noncommunicable Diseases pathogenesis Patients Physical Examination Physicians Radiography, Thoracic Signs and Symptoms, Respiratory Specimen Collection Sputum Therapeutics Woman X-Ray Computed Tomography X-Rays, Diagnostic
2
Acute Pulmonary Embolism Prognosis Factors
A total of 225 hospitalized patients who underwent CTPA examination between May 2018 and November 2021 in our hospital were diagnosed with acute pulmonary embolism and were followed up for 30 days. Follow up information was collected via phone calls. The inclusion criteria were patients diagnosed with APE according to the 2019 European Heart Association Guidelines for Diagnosis and Treatment of Acute Pulmonary Embolism,[4 (link)] 256-slice spiral CTPA examination, clinical data, and follow-up data. The exclusion criteria were other cardiac diseases that caused cardiac enlargement, including chronic pulmonary heart disease, rheumatic heart disease, congenital heart disease, cardiomyopathy, and poor computed tomographic angiography image quality.
All participants were divided into 2 groups, the death group and the non-death group, according to the prognosis data obtained 30 days after onset.
The Wells score, D-dimer, CK, and CK-MB data were also collected when the patients were diagnosed with APE. The Wells score criteria[3 (link)] were as follows: history of pulmonary embolism or deep venous thrombosis, heart rate ≥ 100 beats/minutes, history of operation or braking in the past 4 weeks, hemoptysis, active stage of malignant tumor, DVT-related symptoms, and low possibility of diagnosis other than pulmonary embolism. Each item is counted at 1 point. The normal D-dimer reference value was 0 to 0.243μg/mL. The blood and myocardial enzymes, including CK-MB, had normal reference values < 24MB.
Hu J., Tian X., Liu X., Ma G, & Li C. (2023). Right ventricular area predicts short-term mortality in acute pulmonary embolism based on CT pulmonary angiography: A retrospective study. Medicine, 102(10), e33116.
Publication 2023
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid BLOOD Cardiomyopathies Computed Tomography Angiography Congenital Heart Defects Cor Pulmonale Diagnosis Enzymes Europeans fibrin fragment D Heart Heart Diseases Hemoptysis Isoenzyme CPK MB Myocardium Patients Prognosis Pulmonary Embolism Rate, Heart Rheumatic Heart Disease Staging, Cancer
3
Factors Associated with Drug-Resistant Tuberculosis
Categorical variables that contribute to DR-TB incidence, and DR rates of newly diagnosed and relapse TB cases, were calculated as counts and proportions, respectively. These categorical variables included the study patients’ sexes, ages, occupations, smoking statuses, hemoptysis statuses, and other comorbidities. Pearson chi-square test or Fisher exact test was used to comparing categorical variables as appropriate. Statistically significant differences were considered when the P value was <.05. In addition, differences in DR-TB incidence between newly diagnosed and relapse TB cases were assessed by binary logistic regression analysis, and the factors associated with DR-TB were estimated by adjusted odds ratios (aORs) and 95% confidence intervals (CIs). All statistical analyses were conducted using SPSS 20.0 software (IBM SPSS Statistics for Windows, Version 20.0; SPSS Inc., Chicago, IL).
Zhang H., Yang J., Zhang Z., Hu K., Wu P., Zhang H., Li J., Li M, & Wang X. (2023). Patterns and trends of primary drug-resistant tuberculosis in Chongqing, China, from 2012 to 2020. Medicine, 102(10), e33230.
Publication 2023
Gender Hemoptysis Patients Relapse
4
Longitudinal Study of Physical Activity in Cystic Fibrosis
This was a longitudinal prospective pilot study including CF children aged
between 6 and 15 years and attending the pediatric CF center of the Brussels
Free University, Belgium. The patients were included during a period of 2 months
on the occasion of their follow-up visit. The patients with a medical
contraindication to practice a sport, including hypoxemia, post-pneumothorax
status severe, hemoptysis, or osteoarticular abnormalities, were excluded from
participation. The study was integrated into the regular patient follow-up,
scheduled to take place every 6 weeks, which included 3 follow-up visits. The
first consisted of a routine visit to explain the project. Following the signing
of patient or parental informed consent forms, the second visit was performed at
starting the practice of sport (T0), and the third took place
at month 6. The body mass index (BMI) and spirometric values, including forced
expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and 25% to
75% forced expiratory flow (FEF) were collected, along with the duration of
extracurricular PA (hours/week). Data were expressed as
z-scores based on GLI-2012 reference.10 (link) An incremental shuttle
test (IST) was performed at T0 and month 6 in order to assess
maximum oxygen uptake (VO2max). A variety of tests was applied to evaluate the
children’s physical status. Cardiopulmonary exercise testing (CPET) is
considered the gold standard, yet it requires expensive equipment and
specialized personnel.3 (link),11 (link) Therefore, IST may be a good alternative, given that it is
simple, inexpensive, and reliable.6 (link),12 (link) In this study, we
performed a 15 m IST, conducted in an enclosed corridor on a flat 15 m-long
course. Patients were instructed to run around 2 cones following the rhythm
dictated by the audio signal. Subjects had to run at the prompting of a sound at
regular intervals, to reach the next pole before the next sound goes on. The
15 m IST has 17 levels. Each level includes an increasing number of shuttles and
the speed therefore increases as the level advances. The 15 m test begins with a
running speed above 7.71 km/hour at Level 1 and ends with a speed of 12 km/hour
at Level 17. The end of the test is determined by the patient, when he/she
becomes unable to maintain the required speed, or by the experimenter if the
patient fails to complete a shuttle during the time allowed. Different
parameters (oxygen saturation, heart rate, and respiratory rate) are documented
before, just after, and 3 minutes later the beginning of the test. This test
evaluates aerobic fitness in a maximal effort. A correlation between the test
performance and VO2max can be extrapolated and permits to evaluate the
cardiorespiratory status of the patients. We estimated the VO2max using the
Matsuzaka equation13 (link):

VO2max
(mL/minutes/kg) = (25.9 − 2.21 × G) − 0.0449 × A − 0.831 × Y + 4.12 × MS;
G = 0 for boys and G = 1 for girls; A = age in years; Y = BMI; and
MS = maximum speed.

To evaluate the project’s effects on nutritional and functional parameters, the
patients were classified into 2 groups depending on the PA increases: a first
group without change (PA−) and second group with a minimum increase of
1 hour/week (PA+).
Sputael V., Gaspar V., Weber V., Soussi K., Knoop C, & Hanssens L. (2023). “Just Move It . . . Move It”: A Multidisciplinary Motivational Approach to Improve Physical Activity in Children With Cystic Fibrosis. Global Pediatric Health, 10, 2333794X221150728.
Publication 2023
Boys Child Congenital Abnormality Exercise, Aerobic Exhaling Forced Vital Capacity Gold Hemoptysis Index, Body Mass Oxygen Oxygen Saturation Parent Patients Physical Examination Rate, Heart Respiratory Rate Retinal Cone Sound Spirometry Woman
5
Histopathological Analysis of M. tuberculosis-Infected Lung Tissues
The human study was approved as stated in the ethics statement. The samples used in the present studies were obtained from HIV-negative individuals. These human samples were procured from the period 2009–2010, and therefore were from the time before the onset of the COVID-19 pandemic. M. tuberculosis-infected human lung tissues are routinely obtained following surgery for removal of irreversibly damaged lobes or lungs (bronchiectasis and/or cavitary lung disease). Patients were assessed for extent of pulmonary disease (cavitation and or bronchiectasis) via HRCT. The fitness of each patient to withstand a thoracotomy and lung resection was determined by Karnofsky score, six-minute walk test, spirometry, and arterial blood gas. Assessment of patients with massive hemoptysis included their general condition, effort tolerance prior to hemoptysis, arterial blood gas measurement, serum albumin level and HRCT imaging of the chest. On gross assessment, all pneumonectomies or lobectomies were bronchiectatic, hemorrhagic, variably fibrotic and atelectatic and contained visible tubercles (Table 1). Written informed consent was obtained from patients recruited from King DinuZulu Hospital Complex, a tertiary center for TB patients in Durban, South Africa. Detailed methods for histopathological studies, including histology slide digitization and protocols for immunohistochemistry are presented in S1 Text.
Chen Y., Bharrhan S., Xu J., Sharma T., Wang Y., Salgame P., Zhang J., Nargan K., Steyn A.J., Maglione P.J, & Chan J. (2023). B cells promote granulomatous inflammation during chronic Mycobacterium tuberculosis infection in mice. PLOS Pathogens, 19(3), e1011187.
Publication 2023
6-Minute Walk Test Arteries Atelectasis Blood Gas Analysis Bronchiectasis Chest COVID 19 Fibrosis Hemoptysis Hemorrhage Homo sapiens Immune Tolerance Immunohistochemistry Lung Lung Diseases Mycobacterium tuberculosis Operative Surgical Procedures Patients Pneumonectomy Serum Albumin Spirometry Thoracotomy Tissues

Top products related to «Hemoptysis»

1
Xpert mtb rif by Cepheid
Sourced in United States, Germany
The Xpert MTB/RIF is a molecular diagnostic test developed by Cepheid. It is designed to detect the presence of Mycobacterium tuberculosis (MTB) and identify resistance to the antibiotic rifampicin (RIF) directly from sputum samples. The test utilizes real-time PCR technology to provide rapid and accurate results.
2
Spss for windows version 22 by IBM
Sourced in United States, Japan, United Kingdom
SPSS for Windows version 22.0 is a statistical software package designed to analyze and manage data. It provides a range of tools for data manipulation, statistical analysis, and visualization. The software is compatible with the Windows operating system.
3
Xpert mtb rif assay by Cepheid
Sourced in United States
The Xpert MTB/RIF assay is a rapid molecular diagnostic test developed by Cepheid. It is designed to detect the presence of Mycobacterium tuberculosis (MTB) and identify resistance to the antibiotic rifampicin (RIF) in clinical samples. The test uses real-time PCR technology to provide results within a short timeframe.
4
Quantiferon tb gold plus by Qiagen
Sourced in Germany, United States
QuantiFERON-TB Gold Plus is a blood test designed to aid in the detection of tuberculosis (TB) infection. It measures the body's immune response to the bacteria that cause TB. The test is intended to be used as an aid in diagnosing TB infection.
5
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
6
Spss version 17 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Israel, Thailand
SPSS version 17.0 is a statistical software package developed by IBM. It provides a comprehensive set of tools for data analysis, including data manipulation, visualization, and predictive modeling. The software is designed to handle a wide range of data types and offers a user-friendly interface for conducting complex statistical analyses.
7
Spss for windows version 21 by IBM
Sourced in United States, Japan, United Kingdom
SPSS for Windows version 21.0 is a statistical software package designed for data analysis. It provides a comprehensive set of tools for data manipulation, visualization, and statistical modeling. The software is used for a wide range of applications, including market research, social sciences, and scientific research.
8
Micro spirometer by BD
Sourced in United States, United Kingdom
The Micro Spirometer is a compact, portable device designed for measuring respiratory function. It provides accurate measurements of key spirometric parameters such as forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and peak expiratory flow (PEF). The Micro Spirometer is intended for use in clinical and research settings to assess lung function and monitor respiratory health.

More about "Hemoptysis"

Hemoptysis is the medical term for the expectoration or coughing up of blood or blood-tinged sputum from the lower respiratory tract.
This symptom can be indicative of various underlying conditions, such as lung infections (e.g., tuberculosis, pneumonia), lung cancer, pulmonary embolism, or cardiovascular diseases.
Researchers investigating hemoptysis can leverage PubCompare.ai's AI-driven platform to optimize their research protocols and improve reproducibility.
This advanced tool helps researchers easily locate and compare protocols from literature, preprints, and patents, identifying the best approaches and products.
The AI-powered comparisons take the guesswork out of the research process, ensuring reliable and reproducible results that advance the understanding and management of this important clinical condition.
Some related terms and abbreviations include: - Xpert MTB/RIF: a rapid molecular test for the detection of tuberculosis and rifampicin resistance - SPSS for Windows version 22.0, SAS 9.4, SPSS version 17.0, SPSS for Windows version 21.0: statistical software used in medical research - QuantiFERON-TB Gold Plus: a blood test for detecting latent tuberculosis infection - Micro Spirometer: a device used to measure lung function By utilizing PubCompare.ai's AI-powered platform, researchers can streamline their investigations into hemoptysis and improve the quality and reproducibility of their findings, ultimately contributing to better patient outcomes.